ArticleEBioMedicine2025
Exposure to per- and poly-fluoroalkyl substances in association to later occurrence of type 2 diabetes and metabolic pathway dysregulation in a multiethnic US population.
Article in EBioMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The diabetes exposome: interplay of environmental and genetic determinants in diabetes.Human genomics · 2026Review
- Associations of perfluoroalkyl and polyfluoroalkyl substances with markers of glycaemic control, insulin secretion and sensitivity, and diabetes risk: a systematic review and meta-analyses.EClinicalMedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundGrowing evidence suggests that exposure to per- and polyfluoroalkyl substances (PFAS) are linked to an increased risk of type 2 diabetes (T2D); however, the effect of PFAS mixtures and underlying mechanisms are not well understood. We examined the associations between exposure to PFAS mixture with later T2D diagnosis and underlying metabolic dysregulations.
methodsWe conducted a nested case-control study within BioMe, an electronic health record-linked biobank of >65,000 patients seeking primary care at Mount Sinai Hospital, New York, since 2007. After excluding prevalent T2D cases at baseline, we selected 180 incident T2D cases (33% African Americans, 33% Hispanics, 33% Whites) and 180 age, sex, and ancestry-matched T2D-free controls. In prediagnostic plasma collected at baseline (∼6 years before diagnosis), we quantified seven PFAS and untargeted metabolomic profiles. We used Weighted Quantile Sum regression to evaluate the PFAS mixture association with the odds for incident T2D. We analysed the associations between ∼650 annotated metabolites and the PFAS mixture or T2D odds using Hierarchical Bayesian Weighted Quantile Sum and logistic regression, respectively, adjusting for matching factors and other confounders. Pathway enrichment analyses were performed using Mummichog.
findingsEach tertile increase in the PFAS mixture was associated with higher odds of incident T2D (OR [95% CI] = 1.31 [1.01, 1.70]), with Perfluorooctane Sulfonate (PFOS) having the highest contribution to this association. Metabolites associated with both the PFAS mixture and T2D odds were 5-hydroxytryptophan, glucoheptulose, and sulfolithocholylglycine; the associations with sulfolithocholylglycine survived multiple testing corrections. Pathways associated with both the PFAS mixture and T2D were glutamate metabolism, arginine and proline metabolism, and drug metabolism-cytochrome p450.
interpretationExposure to PFAS mixtures may be associated with increased odds for T2D in multiethnic populations via dysregulations in amino acid and drug metabolism. Larger investigations in multiethnic populations are required to elucidate the potential PFAS contribution to metabolic alterations and T2D risk.
fundingNational Institutes of Health (R01ES033688, P30ES023515, R21ES035148, R35ES030435, R01ES032242, R01ES034521, R01ES029944, R01ES030364, U01HG013288, R21ES037112 and P30ES007048).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.